Effektivnost' i bezopasnost' terapii rozuvastatinom. Rezul'taty 8-nedel'nogo issledovaniya «ot 5 do 40»


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The main purpose of the «from 5 to 40» study was to evaluate the lipid-lowering efficacy and safety of rosuvastatin (Mertenil, «Gedeon Richter») in different doses (from 5 to 40 mg/day) for 8 weeks of treatment in routine clinical practice.

Full Text

Restricted Access

References

  1. Statistical Yearbook of Russia. MoscowRosstat 2009. 795 p. Russian (Российский статистический ежегодник. 2009. Стат. сб. Росстат. М., 2009. 795 c.
  2. Grundy S.M., Cleeman J.I., Merz C.N., et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39. Erratum in: Circulation 2004;110:763.
  3. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur. Heart J. 2007;28:2375-414.
  4. Ray K.K., Seshasai S.R., Erqou S. Statins and allcause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med. 2010;170:1024-31.
  5. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. CTT Collaborators. Lancet. 2012;380(9841):581-90.
  6. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1:CD004816.
  7. Meek C., Wierzbicki A.S., Jewkes C., et al. Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study. Curr. Med. Res. Opin. 2012;28(3):371-78.
  8. Takagi S., Higa M., Ichijo T., et.al. Efficacy of low-dose rosuvastatin in patients with type 2 diabetes and hypohigh-density lipoprotein cholesterolaemia. J. Intern. Med. Res. 2014;42:457.
  9. Blasetto J.W.1, Stein E.A., Brown W.V., et al.Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. Am. J. Cardiol. 2003;91(5A):3-10.
  10. Jones P.H, Davidson M.H., Stein E.A., et al. STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus ator-vastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am. J. Cardiol. 2003; 92:152-60.
  11. Jones P.H, Hunninghake D.B., Ferdinand K.C., et al. STELLAR Study Group. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin. Ther. 2004; 26:1388-99.
  12. Davidson M.H., Ballantyne C.M., et al. Lipidaltering efficacy on the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin. 2006;22:2041-53.
  13. Catapano A.L., Davidson M.H., Ballantyne C.M., et al. Lipid-altering efficacy on the ezetimibe/ simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr. Med. Res. Opin. 2006;22:2041-53.
  14. Ballantyne C.M., Raichlen J.S., Nicholls S.J., et al. ASTEROID Investigators Effect of rosuvastatin therapy on coronary artery stenosis assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation. 2008;117:2458-66.
  15. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart J. 2011;32(14):1769-818.
  16. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. 5-й пересм. М., 2012.
  17. Nicholls S.P., Ballantyne C.M., Barter P.J., et al. Effect of Two Intensive Statin Regimens on Progression of Coronary Disease. N. Engl. J. Med. 2011;365:2078-87.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies